Preview: Ares Management’s Earnings

Ares Management (NYSE:ARES) is set to give its latest quarterly earnings report on Friday, 2023-04-28. Here’s what investors…

Ares Management (NYSE:ARES) is set to give its latest quarterly earnings report on Friday, 2023-04-28. Here’s what investors need to know before the announcement.

Analysts estimate that Ares Management will report an earnings per share (EPS) of $0.82.

Ares Management bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.14, which was followed by a 2.35% increase in the share price the next day.

Here’s a look at Ares Management’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 1.07 0.74 0.69 0.67
EPS Actual 1.21 0.75 0.74 0.65
Price Change % 2.35% 3.7% -0.18% -6.66%

eps graph

Stock Performance

Shares of Ares Management were trading at $81.63 as of April 26. Over the last 52-week period, shares are up 23.41%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Ares Management visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Recap: Euronav Q3 Earnings

Euronav (NYSE:EURN) reported its Q3 earnings results on Thursday, November 3, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings Euronav posted an EPS of $0.08. Revenue was up $124.39 million from the same period last year.

EURN

Read More

Earnings Outlook For Cytek Biosciences

Cytek Biosciences (NASDAQ:CTKB) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Cytek Biosciences will report an earnings per share (EPS) of $0.02.

CTKB

Read More

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

ANEB